Lynch & Associates’s Endologix Inc ELGX Stock Holding History

Lynch & Associates’s Portfolio ELGX Stock Details ELGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,080	Closed	-$21K	–	100
2018 Q3	$21K	Buy	+1,080	New	+$38.5K	0.01%	97

Other funds holding ELGX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Stephens Inc Little Rock, Arkansas $7.99B AUM 21.6% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Lynch & Associates's ELGX Position: Q4 2018 in Review

Lynch & Associates sold out of Endologix Inc (ELGX) in Q4 2018, closing a stake of 1,080 shares — an estimated $21K sold.

Lynch & Associates first reported a position in ELGX in Q3 2018 and held it in 1 quarter. The position peaked at $21K in Q3 2018. 99 funds tracked by Wall St. Rank hold ELGX as of Q4 2018.

Lynch & Associates reported no remaining Endologix Inc position as of Q4 2018 after selling out during the quarter.
Lynch & Associates sold 1,080 Endologix Inc shares in Q4 2018, an estimated $21K.
Lynch & Associates first reported a position in Endologix Inc in Q3 2018 and held it in 1 quarter.
Lynch & Associates's Endologix Inc position peaked at $21K in Q3 2018.
99 funds tracked by Wall St. Rank held Endologix Inc as of Q4 2018.

Based on Lynch & Associates's 13F filing for Q4 2018, filed 10 Jan 2019.